S Ranganathan of LKP Shares and Sec is of the view that Wyeth should give returns of 35% for investors.

Ranganathan told CNBC-TV18, "Wyeth is in the domestic branded space and it has got very strong brands operating in areas with are fast growing like vaccines and the other brands, which are in the gastrointestinal segment because these are acute therapies where in a country like India, we see a lot of volume growth happening. The company already has a 6% dividend yield at these prices. They are sitting on high levels of cash and cash equivalent. It is India centric companies with a minimum or zero exposure to the US and other developed countries. They have not really gone through any fundamental change in their business, means their cost structure also."

He further added, "Typically, the promoters hold more than 50% and because of the fact that they are trading at the lower end of their price to earnings multiple over the last 3-4 years. So basically, you have companies like Wyeth where they are expected to grow their forward earnings at rates, which are higher than the Sensex growth on a valuation basis and compelling valuations in the sense that they trade substantially lower than Sensex valuations. Over a period of one-year, we do expect and believe that the stock should give returns upwards of 35% for investors."